May 1st 2025, 8:00pm
Dr. Neha Mehta-Shah discusses ways patients with rare blood cancers, such as lymphoma, can better understand their specific subtype of disease.
April 4th 2025, 9:00pm
Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles.
March 31st 2025, 5:00pm
As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being reassured everything is fine.
March 27th 2025, 3:00pm
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.
March 22nd 2025, 6:00pm
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
March 21st 2025, 4:00pm
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.
March 18th 2025, 9:00pm
Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.
March 18th 2025, 4:00pm
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.
March 17th 2025, 5:00pm
Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.
March 12th 2025, 7:26pm
It’s easy to think of scientific researchers as existing in a vacuum.
When a Thoughtless Mammogram Reminder Reopened a Deep Cancer Wound
A Lifelong Advocate and Innovator
Personalized Breast Cancer Care for Older Adults Goes Beyond Age
Unmatched Energy, Every Single Day